Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124158) titled 'A study on the efficacy and safety of sequential maintenance treatment with PD-1/CTLA-4 bispecific antibody and anlotinib after combination of PD-1/CTLA-4 bispecific antibody and chemotherapy in second-line treatment of advanced driver gene-negative NSCLC' on May 8.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Nanchang University
Condition:
non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-10
Target Sample Size: Test group:26;
Countries of Recruitment:
China
To know more, visit htt...